Neoadjuvant Immunotherapy: A Promising New Standard of Care

被引：17

作者：

Boydell, Emma ^{[1
]}

Sandoval, Jose L. L. ^{[1
]}

Michielin, Olivier ^{[1
]}

Obeid, Michel ^{[2
]}

Addeo, Alfredo ^{[1
]}

Friedlaender, Alex ^{[1
,3
]}

机构：

[1] Univ Hosp Geneva, CH-1205 Geneva, Switzerland

[2] Univ Hosp Lausanne, CH-1005 Lausanne, Switzerland

[3] Clin Gen Beaulieu, CH-1206 Geneva, Switzerland

来源：

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2023年 / 24卷 / 14期

关键词：

immunotherapy; neoadjuvant; predictive biomarkers; NSCLC; melanoma; urothelial carcinoma; gastric cancer; CELL LUNG-CANCER; MISMATCH-REPAIR DEFICIENCY; STAGE-III; PHASE-II; MICROSATELLITE INSTABILITY; PATHOLOGICAL RESPONSE; IPILIMUMAB IPI; NIVOLUMAB NIVO; PLUS NIVOLUMAB; BREAST-CANCER;

D O I：

10.3390/ijms241411849

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Neoadjuvant immunotherapy has emerged as a promising approach in the treatment of various malignancies, with preclinical studies showing improved immune responses in the preoperative setting. FDA-approved neoadjuvant-immunotherapy-based approaches include triple-negative breast cancer and early non-small cell lung cancer on the basis of improvement in pathological response and event free survival. Nevertheless, current trials have only shown benefits in a fraction of patients. It is therefore crucial to identify predictive biomarkers to improve patient selection for such approaches. This review aims to provide an overview of potential biomarkers of neoadjuvant immunotherapy in early triple-negative breast cancer, bladder cancer, melanoma, non-small cell lung cancer, colorectal cancer and gastric cancer. By the extrapolation of the metastatic setting, we explore known predictive biomarkers, i.e., PD-L1, mismatch repair deficiency and tumour mutational burden, as well as potential early-disease-specific biomarkers. We also discuss the challenges of identifying reliable biomarkers and the need for standardized protocols and guidelines for their validation and clinical implementation.

引用

页数：21

共 107 条

[1] Tumor Mutation Burden-From Hopes to Doubts [J].

Addeo, Alfredo ;

Banna, Giuseppe L. ;

Weiss, Glen J. .

JAMA ONCOLOGY, 2019, 5 (07) :934-935

[2] Neoadjuvant relatlimab and nivolumab in resectable melanoma [J].

Amaria, Rodabe N. ;

Postow, Michael ;

Burton, Elizabeth M. ;

Tezlaff, Michael T. ;

Ross, Merrick, I ;

Torres-Cabala, Carlos ;

Glitza, Isabella C. ;

Duan, Fei ;

Milton, Denai R. ;

Busam, Klaus ;

Simpson, Lauren ;

McQuade, Jennifer L. ;

Wong, Michael K. ;

Gershenwald, Jeffrey E. ;

Lee, Jeffrey E. ;

Goepfert, Ryan P. ;

Keung, Emily Z. ;

Fisher, Sarah B. ;

Betof-Warner, Allison ;

Shoushtari, Alexander N. ;

Callahan, Margaret ;

Coit, Daniel ;

Bartlett, Edmund K. ;

Bello, Danielle ;

Momtaz, Parisa ;

Nicholas, Courtney ;

Gu, Aidi ;

Zhang, Xuejun ;

Korivi, Brinda Rao ;

Patnana, Madhavi ;

Patel, Sapna P. ;

Diab, Adi ;

Lucci, Anthony ;

Prieto, Victor G. ;

Davies, Michael A. ;

Allison, James P. ;

Sharma, Padmanee ;

Wargo, Jennifer A. ;

Ariyan, Charlotte ;

Tawbi, Hussein A. .

NATURE, 2022, 611 (7934) :155-+

[3] Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma [J].

Amaria, Rodabe N. ;

Reddy, Sangeetha M. ;

Tawbi, Hussein A. ;

Davies, Michael A. ;

Ross, Merrick, I ;

Glitza, Isabella C. ;

Cormier, Janice N. ;

Lewis, Carol ;

Hwu, Wen-Jen ;

Hanna, Ehab ;

Diab, Adi ;

Wong, Michael K. ;

Royal, Richard ;

Gross, Neil ;

Weber, Randal ;

Lai, Stephen Y. ;

Ehlers, Richard ;

Blando, Jorge ;

Milton, Denai R. ;

Woodman, Scott ;

Kageyama, Robin ;

Wells, Daniel K. ;

Hwu, Patrick ;

Patel, Sapna P. ;

Lucci, Anthony ;

Hessel, Amy ;

Lee, Jeffrey E. ;

Gershenwald, Jeffrey ;

Simpson, Lauren ;

Burton, Elizabeth M. ;

Posada, Liberty ;

Haydu, Lauren ;

Wang, Linghua ;

Zhang, Shaojun ;

Lazar, Alexanderj ;

Hudgens, Courtney W. ;

Gopalakrishnan, Vancheswaran ;

Reuben, Alexandre ;

Andrews, Miles C. ;

Spencer, Christine N. ;

Prieto, Victor ;

Sharma, Padmanee ;

Allison, James ;

Tetzlaff, Michael T. ;

Wargo, Jennifer A. .

NATURE MEDICINE, 2018, 24 (11) :1649-+

[4] Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study [J].

Andre, Thierry ;

Tougeron, David ;

Piessen, Guillaume ;

de la Fouchardiere, Christelle ;

Louvet, Christophe ;

Adenis, Antoine ;

Jary, Marine ;

Tournigand, Christophe ;

Aparicio, Thomas ;

Desrame, Jerome ;

Lievre, Astrid ;

Garcia-Larnicol, Marie-Line ;

Pudlarz, Thomas ;

Cohen, Romain ;

Memmi, Salome ;

Vernerey, Dewi ;

Henriques, Julie ;

Lefevre, Jeremie H. ;

Svrcek, Magali .

JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (02) :255-+

[5] Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].

Argiles, G. ;

Tabernero, J. ;

Labianca, R. ;

Hochhauser, D. ;

Salazar, R. ;

Iveson, T. ;

Laurent-Puig, P. ;

Quirke, P. ;

Yoshino, T. ;

Taieb, J. ;

Martinelli, E. ;

Arnold, D. .

ANNALS OF ONCOLOGY, 2020, 31 (10) :1291-1305

[6] Biomarker: Predictive or Prognostic? [J].

Ballman, Karla V. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (33) :3968-+

[7] Preoperative Chemoradiotherapy plus Nivolumab before Surgery in Patients with Microsatellite Stable and Microsatellite Instability-High Locally Advanced Rectal Cancer [J].

Bando, Hideaki ;

Tsukada, Yuichiro ;

Inamori, Koji ;

Togashi, Yosuke ;

Koyama, Shohei ;

Kotani, Daisuke ;

Fukuoka, Shota ;

Yuki, Satoshi ;

Komatsu, Yoshito ;

Homma, Shigenori ;

Taketomi, Akinobu ;

Uemura, Mamoru ;

Kato, Takeshi ;

Fukui, Makoto ;

Wakabayashi, Masashi ;

Nakamura, Naoki ;

Kojima, Motohiro ;

Kawachi, Hiroshi ;

Kirsch, Richard ;

Yoshida, Tsutomu ;

Suzuki, Yutaka ;

Sato, Akihiro ;

Nishikawa, Hiroyoshi ;

Ito, Masaaki ;

Yoshino, Takayuki .

CLINICAL CANCER RESEARCH, 2022, 28 (06) :1136-1146

[8] The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer [J].

Banna, G. L. ;

Cortellini, A. ;

Cortinovis, D. L. ;

Tiseo, M. ;

Aerts, J. G. J., V ;

Barbieri, F. ;

Giusti, R. ;

Bria, E. ;

Grossi, F. ;

Pizzutilo, P. ;

Berardi, R. ;

Morabito, A. ;

Genova, C. ;

Mazzoni, F. ;

Di Noia, V ;

Signorelli, D. ;

Gelibter, A. ;

Macerelli, M. ;

Rastelli, F. ;

Chiari, R. ;

Rocco, D. ;

Gori, S. ;

De Tursi, M. ;

Di Marino, P. ;

Mansueto, G. ;

Zoratto, F. ;

Filetti, M. ;

Montrone, M. ;

Citarella, F. ;

Marco, R. ;

Cantini, L. ;

Nigro, O. ;

D'Argento, E. ;

Buti, S. ;

Minuti, G. ;

Landi, L. ;

Guaitoli, G. ;

Lo Russo, G. ;

De Toma, A. ;

Donisi, C. ;

Friedlaender, A. ;

De Giglio, A. ;

Metro, G. ;

Porzio, G. ;

Ficorella, C. ;

Addeo, A. .

ESMO OPEN, 2021, 6 (02)

[9] Biological Rationale for Peripheral Blood Cell-Derived Inflammatory Indices and Related Prognostic Scores in Patients with Advanced Non-Small-Cell Lung Cancer [J].

Banna, Giuseppe Luigi ;

Friedlaender, Alex ;

Tagliamento, Marco ;

Mollica, Veronica ;

Cortellini, Alessio ;

Rebuzzi, Sara Elena ;

Prelaj, Arsela ;

Naqash, Abdul Rafeh ;

Auclin, Edouard ;

Garetto, Lucia ;

Mezquita, Laura ;

Addeo, Alfredo .

CURRENT ONCOLOGY REPORTS, 2022, 24 (12) :1851-1862

[10] A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9-15 PROMISE-meso phase III trial [J].

Banna, Giuseppe Luigi ;

Addeo, Alfredo ;

Zygoura, Panagiota ;

Tsourti, Zoi ;

Popat, Sanjay ;

Curioni-Fontecedro, Alessandra ;

Nadal, Ernest ;

Shah, Riyaz ;

Pope, Anthony ;

Fisher, Patricia ;

Spicer, James ;

Roy, Amy ;

Gilligan, David ;

Gautschi, Oliver ;

Janthur, Wolf-Dieter ;

Lopez-Castro, Rafael ;

Roschitzki-Voser, Heidi ;

Dafni, Urania ;

Peters, Solange ;

Stahel, Rolf A. .

LUNG CANCER, 2022, 169 :77-83

← 1 2 3 4 5 6 7 8 9 10 →